| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
RO495 targets TYK2 (non-receptor tyrosine-protein kinase 2). It acts as a potent inhibitor of TYK2 kinase activity. The compound inhibits TYK2 with an IC50 of 1.5 nM as tested in cell-based assays.
|
|---|---|
| ln Vitro |
In vitro, RO495 is a potent inhibitor of TYK2 with an IC50 of 1.5 nM as tested in cell-based assays. It is a research compound for studying TYK2 function. Specific cellular activity data are not detailed in the available sources.
|
| ln Vivo |
In vivo activity data for RO495 are not extensively detailed in the available sources. The compound is a research tool for studying TYK2 function in immune signaling. Specific in vivo efficacy data in animal models have not been reported.
|
| Enzyme Assay |
The in vitro enzyme assay for RO495 involves measuring the inhibition of TYK2 kinase activity. Recombinant TYK2 is incubated with a substrate peptide and ATP in the presence of varying compound concentrations. The IC50 value (1.5 nM) is determined by quantifying the reduction in substrate phosphorylation using techniques such as radioactive or fluorescence-based assays.
|
| Cell Assay |
Cellular assays for RO495 are performed using cell lines treated with the compound at varying concentrations. TYK2 phosphorylation and downstream signaling are assessed by Western blotting using phospho-specific antibodies.
|
| Animal Protocol |
In vivo animal studies for RO495 are not detailed in the available sources. The compound is a research tool for studying TYK2 function. Specific animal models, dosing regimens, and efficacy data have not been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for RO495 are not available in the provided sources. The compound has a molecular weight of 389.24 g/mol. Powder formulations should be stored at -20°C for long-term storage or at 0-4°C for short-term storage.
|
| Toxicity/Toxicokinetics |
Toxicity data for RO495 are not reported in the available sources. As a research compound, it is not intended for therapeutic use. Specific toxicological profiles have not been characterized.
|
| References | |
| Additional Infomation |
RO495 is a research compound for studying TYK2 function in immune signaling. It is a potent TYK2 inhibitor with an IC50 of 1.5 nM in cell-based assays. The compound is available from commercial suppliers for research use only.
|
| Molecular Formula |
C17H14CL2N6O
|
|---|---|
| Molecular Weight |
389.2387
|
| Exact Mass |
388.06
|
| CAS # |
1258296-60-4
|
| PubChem CID |
57519505
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.739
|
| LogP |
4.36
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
474
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=NC(=N1)N)NC2=NC=CC(=C2)NC(=O)C3=C(C=CC=C3Cl)Cl
|
| InChi Key |
LNGDQKGREFSTHB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H14Cl2N6O/c1-9-7-14(25-17(20)22-9)24-13-8-10(5-6-21-13)23-16(26)15-11(18)3-2-4-12(15)19/h2-8H,1H3,(H4,20,21,22,23,24,25,26)
|
| Chemical Name |
N-[2-[(2-amino-6-methylpyrimidin-4-yl)amino]pyridin-4-yl]-2,6-dichlorobenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~256.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5691 mL | 12.8455 mL | 25.6911 mL | |
| 5 mM | 0.5138 mL | 2.5691 mL | 5.1382 mL | |
| 10 mM | 0.2569 mL | 1.2846 mL | 2.5691 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
